Thus, the presented preliminary data support the idea that selective GPR18 antagonism represents a promising avenue for the further research, and that the development of selective GPR18 antagonists for the treatment of obesity might result in valuable and promising outcomes. The gene discussed is GPR18; the disease is obesity due to melanocortin 4 receptor deficiency.